SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that its next-generation automated insulin delivery ...
A greater proportion of patients with type 1 diabetes who used automated insulin delivery systems vs multiple daily injections achieved the Healthcare Effectiveness Data and Information Set (HEDIS) ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance for ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today presented new real-world insights from a survey on Tandem Mobi ...
First and only commercially available AID technology for pregnancy use in the U.S. Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today ...
Medical Device Network on MSN
Tandem secures CE mark for AID systems in T2D and T1D with pregnancy
The regulatory clearance covers the t:slim X2 and Tandem Mobi insulin pumps with Control-IQ+ technology.
Tandem Diabetes Care's t:slim X2 Insulin Pump Automated Insulin Delivery System is now the first to incorporate the Abbott FreeStyle Libre 2 Plus Sensor for users in the United States. The FreeStyle ...
"The greatest benefit was observed in participants with the worst baseline glycemic control, in whom the auto-bolus feature of the Control-IQ algorithm appears to have substantial impact," wrote the ...
– Additional data presented at the 18th International Conference on Advanced Technologies & Treatments for Diabetes – Results published in NEJM demonstrate significant improvements in time in range ...
Tandem Diabetes Care has received approval from the US Food and Drug Administration (FDA) for its Control-IQ+ automated insulin delivery technology to be used during pregnancy in individuals with type ...
The FDA expansion came after Tandem and Dexcom published a study earlier this year focusing specifically on toddlers’ use of their combined automated insulin delivery system. After 13 weeks, kids saw ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results